Enlaza Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 66

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $15M

  • Investors
  • 13

Enlaza Therapeutics General Information

Description

Developer of covalent protein therapeutics intended to deliver targeted treatments for oncology and autoimmune diseases. The company offers a novel synthetic biology platform that uses covalent bonds to lock onto a target protein that provides sustained occupancy and prolonged biologic effect with minimal systemic exposure, enabling healthcare professionals to treat various diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 280, La Jolla
  • San Diego, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 11099 North Torrey Pines Road
  • Suite 280, La Jolla
  • San Diego, CA 92037
  • United States
+1 (858)

Enlaza Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enlaza Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A1) 10-Sep-2025 $15M Completed Generating Revenue
2. Early Stage VC (Series A) 30-Apr-2024 Completed Startup
1. Seed Round 15-Dec-2022 $61M $61M Completed Startup
To view Enlaza Therapeutics’s complete valuation and funding history, request access »

Enlaza Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
To view Enlaza Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Enlaza Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of covalent protein therapeutics intended to deliver targeted treatments for oncology and autoimmune diseases.
Drug Discovery
San Diego, CA
66 As of 2026

Cambridge, United Kingdom
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enlaza Therapeutics Competitors (3)

One of Enlaza Therapeutics’s 3 competitors is Dunad Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dunad Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Avilar Therapeutics Venture Capital-Backed Waltham, MA
Matchpoint Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 3 of 3 competitors. Get the full list »

Enlaza Therapeutics Patents

Enlaza Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026107097-A1 Self-immolative linkers and conjugates thereof Pending 13-Nov-2024
AU-2023275779-A1 Crosslinking multispecific antibodies Pending 27-May-2022
EP-4532564-A1 Crosslinking multispecific antibodies Pending 27-May-2022
EP-4532564-A4 Crosslinking multispecific antibodies Pending 27-May-2022
US-20250353926-A1 Crosslinking multispecific antibodies Pending 27-May-2022 C07K16/30
To view Enlaza Therapeutics’s complete patent history, request access »

Enlaza Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enlaza Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Amgen Ventures Corporate Venture Capital Minority
Avalon Ventures Venture Capital Minority
Bregua Corporation Venture Capital Minority
JP Morgan Asset Management Asset Manager Minority
You’re viewing 5 of 13 investors. Get the full list »

Enlaza Therapeutics FAQs

  • When was Enlaza Therapeutics founded?

    Enlaza Therapeutics was founded in 2020.

  • Where is Enlaza Therapeutics headquartered?

    Enlaza Therapeutics is headquartered in San Diego, CA.

  • What is the size of Enlaza Therapeutics?

    Enlaza Therapeutics has 66 total employees.

  • What industry is Enlaza Therapeutics in?

    Enlaza Therapeutics’s primary industry is Drug Discovery.

  • Is Enlaza Therapeutics a private or public company?

    Enlaza Therapeutics is a Private company.

  • What is the current valuation of Enlaza Therapeutics?

    The current valuation of Enlaza Therapeutics is .

  • What is Enlaza Therapeutics’s current revenue?

    The current revenue for Enlaza Therapeutics is .

  • How much funding has Enlaza Therapeutics raised over time?

    Enlaza Therapeutics has raised $176M.

  • Who are Enlaza Therapeutics’s investors?

    Alexandria Venture Investments, Amgen Ventures, Avalon Ventures, Bregua Corporation, and JP Morgan Asset Management are 5 of 13 investors who have invested in Enlaza Therapeutics.

  • Who are Enlaza Therapeutics’s competitors?

    Dunad Therapeutics, Avilar Therapeutics, and Matchpoint Therapeutics are competitors of Enlaza Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process